Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-25T11:00:20.065Z Has data issue: false hasContentIssue false
  • English
  • Français

Effectiveness of Zuclopenthixol Compared with Haloperidol in the Treatment of Behavioural Disturbances in Learning Disabled Patients

Published online by Cambridge University Press:  02 January 2018

Ulrik F. Malt ,
Roy Nystad ,
Torkel Bache ,
Ole Noren ,
Mary Sjaastad ,
Knut Ove Solberg ,
Sverre T⊘nseth ,
Peter Zachariassen  and
Eli Mæhlum
Ulrik F. Malt*
Affiliation:
University of Oslo, Department of Psychosomatic and Behavioural Medicine, National Hospital, N-0027 Oslo
Roy Nystad
Affiliation:
Adult Habilitation Unit, Department of Neurology, Ullevål Hospital, N-0407 Oslo
Torkel Bache
Affiliation:
åkershagan Central Institution for the Mentally Retarded, N-2312 Ottestad
Ole Noren
Affiliation:
åkershagan Central Institution for the Mentally Retarded, N-2312 Ottestad
Mary Sjaastad
Affiliation:
åkershagan Central Institution for the Mentally Retarded, N-2312 Ottestad
Knut Ove Solberg
Affiliation:
Adult Habilitation Unit, Department of Neurology, Ullevål Hospital, N-0407 Oslo
Sverre T⊘nseth
Affiliation:
åkershagan Central Institution for the Mentally Retarded, N-2312 Ottestad
Peter Zachariassen
Affiliation:
åkershagan Central Institution for the Mentally Retarded, N-2312 Ottestad
Eli Mæhlum
Affiliation:
Lundbeck Ltd, N-1301 Sandvika, Norway
*
Professor Malt, Department of Psychosomatic and Behavioural Medicine, National Hospital, N-0027 Oslo, Norway
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

We compared the efficacy of two neuroleptics with different receptor profiles (zuclopenthixol and haloperidol) in learning disabled patients with behavioural disturbance.

Method

A double-blind crossover study (2×8 weeks; n = 34), interrupted by a two-week single-blind washout period, was employed. Assessments included the Schedule for Handicaps, Behaviour, and Skills (SHBS) and Clinical Global Impression (CGI).

Results

The SHBS score was significantly reduced for the zuclopenthixol cohort only. End-point analysis between the two drugs also showed an enhanced effect for zuclopenthixol over haloperidol. CGI scores did not reveal significant differences between the two drugs.

Conclusion

Zuclopenthixol may be superior to haloperidol for the treatment of behavioural disturbances in mentally retarded subjects.

Type
Papers
Information
The British Journal of Psychiatry , Volume 166 , Issue 3 , March 1995 , pp. 374 - 377
Copyright
Copyright © 1995 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aman, M. G. & Singh, N. N. (1988) Patterns of drug use, methodological considerations, measurement techniques, and future trends. In Psychopharmacology of the Development Disabilities (eds Aman, M. G., Singh, N. N.), pp. 1–20. New York: Springer.CrossRefGoogle Scholar
Aman, M. G., Teechan, C. J., White, A. J., et al (1989) Haloperidol treatment with chronically medicated residents: dose effects on clinical behaviour and reinforcement contingencies. American Journal of Mental Retardation, 93, 452–460.Google ScholarPubMed
Izmeth, M. G., Khan, S. Y., Kumarajeewa, D. I., et al (1988) Zuclopenthixol decanoate in the management of behavioural disorders in mentally handicapped patients. Pharmatherapeutica, 5, 217–227.Google ScholarPubMed
Karsten, D., Kivimaeki, T., Linna, S.-L., et al (1981) Neuroleptic treatment of oligophrenic patients. Acta Psychiatrica Scandinavica, 64 (suppl. 294), 39–45.Google Scholar
Linaker, O. (1990) Frequency of and determinants for psychotropic drug use in an institution for the mentally retarded. British Journal of Psychiatry, 156, 525–530.CrossRefGoogle Scholar
Lingjærde, O., Ahlfors, U. G., Bech, P., et al (1987) The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica, 76 (suppl. 334).CrossRefGoogle Scholar
Lund, J. (1989) Measuring behaviour disorder in mental handicap. British Journal of Psychiatry, 155, 379–383.CrossRefGoogle ScholarPubMed
Mlele, T. J. & Wiley, Y. V. (1986) Clopenthixol decanoate in the management of aggressive mentally handicapped patients. British Journal of Psychiatry, 149, 373–376.CrossRefGoogle ScholarPubMed
Shrout, P. E. & Fleiss, J. L. (1979) Intraclass correlations: uses in assessing rater reliability. Psychological Bulletin, 86, 420–428.CrossRefGoogle ScholarPubMed
Singh, I. & Owino, W. J. (1992) A double-blind comparison of zuclopenthixol tablets with placebo in the treatment of mentally handicapped in-patients with associated behavioural problems. Journal of Intellectual Disability Research, 36, 541–549.CrossRefGoogle Scholar
World Health Organization (1992) The ICD–10 Classification of Mental and Behavioural Disorders. Geneva: WHO.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.